Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
Background Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid p...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2024-01-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://e-dmj.org/upload/pdf/dmj-2022-0402.pdf |
| _version_ | 1797321067803443200 |
|---|---|
| author | Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim |
| author_facet | Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim |
| author_sort | Ji Hye Han |
| collection | DOAJ |
| description | Background Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid profile, insulin sensitivity, and vascular inflammatory response in patients with T2DM. Methods A total of 101 patients with T2DM and dyslipidemia were randomized to either rosuvastatin monotherapy (5 mg/day, n=47) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day, n=45) and treated for 12 weeks. Serum lipids, glucose, insulin, soluble intercellular adhesion molecule-1 (sICAM-1), and peroxiredoxin 4 (PRDX4) levels were determined before and after 12 weeks of treatment. Results The reduction in low density lipoprotein cholesterol (LDL-C) by more than 50% from baseline after treatment was more in the combination therapy group. The serum sICAM-1 levels increased significantly in both groups, but there was no difference between the two groups. The significant changes in homeostasis model assessment of insulin resistance (HOMA-IR) and PRDX4 were confirmed only in the subgroup in which LDL-C was reduced by 50% or more in the combination therapy group. However, after adjusting for diabetes mellitus duration and hypertension, the changes in HOMA-IR and PRDX4 were not significant between the two groups. Conclusion Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response. |
| first_indexed | 2024-03-08T04:52:12Z |
| format | Article |
| id | doaj.art-fdea9a06fe8f4ad18c149796777819f8 |
| institution | Directory Open Access Journal |
| issn | 2233-6079 2233-6087 |
| language | English |
| last_indexed | 2024-03-08T04:52:12Z |
| publishDate | 2024-01-01 |
| publisher | Korean Diabetes Association |
| record_format | Article |
| series | Diabetes & Metabolism Journal |
| spelling | doaj.art-fdea9a06fe8f4ad18c149796777819f82024-02-08T04:09:37ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872024-01-0148111212110.4093/dmj.2022.04022793Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes MellitusJi Hye Han0Kyong Hye Joung1Jun Choul Lee2Ok Soon Kim3Sorim Choung4Ji Min Kim5Yea Eun Kang6Hyon-Seung Yi7Ju Hee Lee8Bon Jeong Ku9Hyun Jin Kim10 Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, KoreaBackground Type 2 diabetes mellitus (T2DM) induces endothelial dysfunction and inflammation, which are the main factors for atherosclerosis and cardiovascular disease. The present study aimed to compare the effects of rosuvastatin monotherapy and rosuvastatin/ezetimibe combination therapy on lipid profile, insulin sensitivity, and vascular inflammatory response in patients with T2DM. Methods A total of 101 patients with T2DM and dyslipidemia were randomized to either rosuvastatin monotherapy (5 mg/day, n=47) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day, n=45) and treated for 12 weeks. Serum lipids, glucose, insulin, soluble intercellular adhesion molecule-1 (sICAM-1), and peroxiredoxin 4 (PRDX4) levels were determined before and after 12 weeks of treatment. Results The reduction in low density lipoprotein cholesterol (LDL-C) by more than 50% from baseline after treatment was more in the combination therapy group. The serum sICAM-1 levels increased significantly in both groups, but there was no difference between the two groups. The significant changes in homeostasis model assessment of insulin resistance (HOMA-IR) and PRDX4 were confirmed only in the subgroup in which LDL-C was reduced by 50% or more in the combination therapy group. However, after adjusting for diabetes mellitus duration and hypertension, the changes in HOMA-IR and PRDX4 were not significant between the two groups. Conclusion Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.http://e-dmj.org/upload/pdf/dmj-2022-0402.pdfdiabetes mellitus, type 2ezetimibeinflammationinsulin resistancerosuvastatin calcium |
| spellingShingle | Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus Diabetes & Metabolism Journal diabetes mellitus, type 2 ezetimibe inflammation insulin resistance rosuvastatin calcium |
| title | Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus |
| title_full | Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus |
| title_fullStr | Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus |
| title_short | Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus |
| title_sort | comparative efficacy of rosuvastatin monotherapy and rosuvastatin ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus |
| topic | diabetes mellitus, type 2 ezetimibe inflammation insulin resistance rosuvastatin calcium |
| url | http://e-dmj.org/upload/pdf/dmj-2022-0402.pdf |
| work_keys_str_mv | AT jihyehan comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT kyonghyejoung comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT junchoullee comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT oksoonkim comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT sorimchoung comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT jiminkim comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT yeaeunkang comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT hyonseungyi comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT juheelee comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT bonjeongku comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus AT hyunjinkim comparativeefficacyofrosuvastatinmonotherapyandrosuvastatinezetimibecombinationtherapyoninsulinsensitivityandvascularinflammatoryresponseinpatientswithtype2diabetesmellitus |